Crizonix – A Project of Reinforcelab
Crizonix is the global first generic preparation of Crizotinib. CRIZONIX is indicated as the first-line treatment of adults with ALK-positive advanced Non Small Cell Lung Cancer(NSCLC) and ROS1 (+) NSCLC. Crizotinib is an ALK and ROS1 (c-ros oncogene 1, receptor tyrosine kinase) inhibitor. This Crizonix is 13 times affordable than originator and the quality of the product is to that of International Standard GMP compliant. Beacon Pharmaceuticals Limited manufactured this product in a dedicated oncology facility. They are providing worldwide delivery support.
During this project we have completely changed the layout and place the menu in the side bar. At the same time, we have ensured best quality design for the website to make it user friendly for the customers. Also, set several call action to increase the sales rate of the product’s website.